{"filing":{"accession_number":"0001178913-26-004591","cik":"0001498403","ticker":"BLRX","company_name":"BioLineRx Ltd.","form":"6-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"zk2636152.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498403/000117891326004591/zk2636152.htm"},"events":[{"id":34863,"run_id":32102,"accession_number":"0001178913-26-004591","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of BioLineRx's Annual General Meeting of Shareholders held on September 23, 2026, reporting shareholder approval of five proposals: re-election of three Class III directors (Dr. Aharon Schwartz, Dr. Sandra Panem, Dr. Shaoyu Yan), increase in authorized share capital and Articles amendment, equity compensation grants to CEO Philip Serlin and certain directors, and reappointment of auditors. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the director elections and auditor reappointment are material governance matters affecting investor assessment.","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-09-24","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":38719,"accession_number":"0001178913-26-004591","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of BioLineRx's Annual General Meeting of Shareholders held on September 23, 2026, reporting shareholder approval of five proposals: re-election of three Class III directors (Dr. Aharon Schwartz, Dr. Sandra Panem, Dr. Shaoyu Yan), increase in authorized share capital and Articles amendment, equity compensation grants to CEO Philip Serlin and certain directors, and reappointment of auditors. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the director elections and auditor reappointment are material governance matters affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:07:46.087574+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-09-24"}]}